Related references
Note: Only part of the references are listed.Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP)
Andres F. Cardona et al.
FRONTIERS IN ONCOLOGY (2019)
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Charles M. Rudin et al.
NATURE REVIEWS CANCER (2019)
POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer
Yu-Han Huang et al.
GENES & DEVELOPMENT (2018)
Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer
Karen McColl et al.
ONCOTARGET (2017)
Small-cell lung cancer: what we know, what we need to know and the path forward
Adi F. Gazdar et al.
NATURE REVIEWS CANCER (2017)
Validation of OncoPanel A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer
Elizabeth P. Garcia et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2017)
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
Gurkan Mollaoglu et al.
CANCER CELL (2017)
Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression
Eric Polley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?
Sandra Cristea et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer
Hidenori Kitai et al.
CANCER DISCOVERY (2016)
Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression
Eric Polley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma
Michael K. Kiessling et al.
PLOS ONE (2016)
f Institutional implementation of clinical tumor profiling on an unselected cancer population
Lynette M. Sholl et al.
JCI INSIGHT (2016)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263
E. F. Greenberg et al.
CELL DEATH & DISEASE (2015)
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer
Erin M. Tricker et al.
CANCER DISCOVERY (2015)
Mutant HRAS as novel target for MEK and mTOR inhibitors
Michael K. Kiessling et al.
ONCOTARGET (2015)
Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing
J. -M. Sun et al.
ANNALS OF ONCOLOGY (2015)
RET Mutation and Expression in Small-Cell Lung Cancer
Snehal Dabir et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes
Anna M. Varghese et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma
Sean T. Bailey et al.
PLOS ONE (2014)
Mutant NRASQ61 shares signaling similarities across various cancer types - potential implications for future therapies
Igor Vujic et al.
ONCOTARGET (2014)
Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR
Qingsong Liu et al.
CANCER RESEARCH (2013)
Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma
Federica Catalanotti et al.
CLINICAL CANCER RESEARCH (2013)
Characteristics of Lung Cancers Harboring NRAS Mutations
Kadoaki Ohashi et al.
CLINICAL CANCER RESEARCH (2013)
TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma
Ryan B. Corcoran et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer
Moshe Elkabets et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas
William D. Travis
MODERN PATHOLOGY (2012)
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Andrew C. Hsieh et al.
NATURE (2012)
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer
Charles M. Rudin et al.
NATURE GENETICS (2012)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Martin Peifer et al.
NATURE GENETICS (2012)
Small Cell Lung Cancer Doubling Time and its Effect on Clinical Presentation: A Concise Review
Kassem Harris et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2012)
A Functional Role for Tumor Cell Heterogeneity in a Mouse Model of Small Cell Lung Cancer
Joaquim Calbo et al.
CANCER CELL (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
Mohammad Atefi et al.
PLOS ONE (2011)
Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer
Matthew T. Burger et al.
ACS MEDICINAL CHEMISTRY LETTERS (2011)
AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
Christine M. Chresta et al.
CANCER RESEARCH (2010)
Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells
Y. N. Vashisht Gopal et al.
CANCER RESEARCH (2010)
MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2010)
The EML4-ALK Fusion Gene Is Involved in Various Histologic Types of Lung Cancers From Nonsmokers With Wild-type EGFR and KRAS
Daisy Wing-Sze Wong et al.
CANCER (2009)
The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition
Sai-Hong Ignatius Ou et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
Florence I. Raynaud et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Somatic mutations affect key pathways in lung adenocarcinoma
Li Ding et al.
NATURE (2008)
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
G. Attard et al.
ONCOGENE (2008)
ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms
Dexin Kong et al.
CANCER SCIENCE (2007)
TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort
F. Demichelis et al.
ONCOGENE (2007)
RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation
Philippe P. Roux et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Share Paper
